Detalhe da pesquisa
1.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
2.
Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study.
Hepatol Res
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349813
3.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
4.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455517
5.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307798
6.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552968
7.
Spleen stiffness in patients with chronic liver disease evaluated by 2-D shear wave elastography with ultrasound multiparametric imaging.
Hepatol Res
; 53(2): 93-103, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149642
8.
Association of abnormal glucose tolerance with liver-related disease and cardiovascular diseases in patients with chronic hepatitis C.
Hepatol Res
; 53(9): 806-814, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183992
9.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020416
10.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306040
11.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231943
12.
Comparisons of Hepatobiliary Phase Imaging Using Combinations of Parallel Imaging and Variable Degrees of Compressed Sensing With Use of Parallel Imaging Alone.
J Comput Assist Tomogr
; 47(4): 524-529, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790909
13.
Role of B Cell-Activating Factor in Fibrosis Progression in a Murine Model of Non-Alcoholic Steatohepatitis.
Int J Mol Sci
; 24(3)2023 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36768854
14.
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
Am J Gastroenterol
; 117(10): 1605-1613, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973168
15.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103846
16.
Measurement of multiple spleen lengths is not necessary for non-invasive prediction of high-risk esophagogastric varices.
Hepatol Res
; 52(2): 187-198, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570948
17.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080087
18.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799975
19.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35633504
20.
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology
; 99(8): 518-527, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906189